Sign In
Buy ARGX
$813.14
+10.97 (+1.37%)
At Close: Jun 03, 2026
argenx Highlights 2026 Strategic Priorities
01:00am, Monday, 12'th Jan 2026
Reported $4.15 billion (YoY growth of +90%) in preliminary* full-year 2025 global product net sales, inclusive of $1.29 billion in fourth quarter sales
argenx to Present at 44th Annual J.P. Morgan Healthcare Conference
01:00am, Tuesday, 06'th Jan 2026
January 6, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today
argenx Announces Leadership Transition Marking Next Evolution of Growth
01:00am, Monday, 05'th Jan 2026
Tim Van Hauwermeiren to transition from CEO to Non-Executive Director and Chairman of Board of Directors and Karen Massey to transition from COO to CEO and Executive Director
argenex SE (NASDAQ:ARGX) Given Average Recommendation of “Moderate Buy” by Brokerages
01:54am, Friday, 02'nd Jan 2026
Shares of argenex SE (NASDAQ: ARGX - Get Free Report) have been given an average recommendation of "Moderate Buy" by the twenty-six research firms that are covering the stock, Marketbeat reports. Six
KROS or ARGX: Which Is the Better Value Stock Right Now?
12:40pm, Tuesday, 30'th Dec 2025
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Keros Therapeutics, Inc. (KROS) or argenex SE (ARGX). But which of these two stocks presents
5 Top Stocks With High 2026 Earnings Growth Targets
05:00am, Monday, 22'nd Dec 2025
The S&P 500 experienced sharp swings in 2025 due to shifts in trade policy, AI speculation, and rate cuts, while corporate profits remained resilient. Broader AI adoption and steady economic growth ar
This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter
06:25pm, Friday, 19'th Dec 2025
CNBC's “Closing Bell Overtime” team discusses why the biotech recovery may continue into 2026 with Salveen Richter, lead U.S. biotech analyst at Goldman Sachs Research.
Pre-Market Stock Futures: Futures are trading higher on Thursday as we grind closer to the Christmas holiday, which is just a week off now. The song remains the same for the AI/Datacenter trade, and p
Touchstone Sands Capital International Growth Equity Fund Q3 2025 Portfolio Update
07:00am, Tuesday, 16'th Dec 2025
The Touchstone Sands Capital International Growth Fund (Class A Shares, Load Waived) underperformed the MSCI ACWI ex-U.S. Index for the quarter ended September 30, 2025. The top absolute contributors
Argenx Halts Phase 3 Thyroid Eye Disease Trial, Peers Like Viridian Therapeutics To Benefit
10:25am, Monday, 15'th Dec 2025
Argenx SE (NASDAQ: ARGX) on Monday announced it would discontinue the Phase 3 UplighTED studies evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with mode
Argenx Flops, As Viridian Celebrates, On Surprise Setback For Vyvgart Powerhouse
09:54am, Monday, 15'th Dec 2025
Argenx stock toppled Monday after the biotech scrapped plans to develop its blockbuster drug, Vyvgart, for thyroid eye disease.
Argenx, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session
08:06am, Monday, 15'th Dec 2025
U.S. stock futures were higher this morning, with the Dow futures gaining around 200 points on Monday.
Stock Market Today: Dow Futures, S&P 500 Advance Ahead Of Key Economic Data: iRobot, Argenx, MindWalk In Focus
04:41am, Monday, 15'th Dec 2025
U.S. stock futures are up early Monday morning, following a mixed week that saw rotation out of expensive tech stocks in favor of value, despite the third consecutive interest rate cut on Wednesday.
argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease
01:00am, Monday, 15'th Dec 2025
15 December, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmu
AWM Investment Company Inc. Decreases Stake in argenex SE $ARGX
07:08am, Saturday, 13'th Dec 2025
AWM Investment Company Inc. decreased its position in argenex SE (NASDAQ: ARGX) by 34.8% during the second quarter, according to the company in its most recent filing with the Securities and Exchange
